Drug Trial Radar · NCT03930615
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Jun 21, 2019
Primary completion
Oct 27, 2021
Study completion Mar 16, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It was hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.
Conditions
- Cytomegalovirus Infection
Interventions
LetermovirDrug
LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
PlaceboDrug
Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplantTime frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Locations
32 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center ( Site 0158)
Duarte, California
University of California Davis Medical Center ( Site 0156)
Sacramento, California
University of Miami, Sylvester Comprehensive Cancer Center ( Site 0160)
Miami, Florida
Indiana Blood and Marrow Transplantation ( Site 0175)
Indianapolis, Indiana
Brigham & Women's Hospital ( Site 0161)
Boston, Massachusetts
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0174)
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center ( Site 0164)
New York, New York
Duke University Medical Center ( Site 0169)
Durham, North Carolina
The University of Texas MD Anderson Cancer Center ( Site 0154)
Houston, Texas
Fred Hutchinson Cancer Research Center ( Site 0152)
Seattle, Washington
CHU Hopital Saint Antoine ( Site 0036)
Paris, France
Centre Hospitalier Universitaire Dupuytren ( Site 0182)
Limoges, Haute-Vienne, France
Hopital Saint Eloi ( Site 0031)
Montpellier, Herault, France
Centre Hopitalier Lyon Sud ( Site 0039)
Pierre-Bénite, Rhone, France
CHU Henri Mondor ( Site 0032)
Créteil, Val-de-Marne, France
Institut Gustave Roussy ( Site 0038)
Villejuif, Val-de-Marne, France
Universitaetsklinikum Heidelberg-Medizinische Klinik V ( Site 0042)
Heidelberg, Baden-Wurttemberg, Germany
Universitaetsklinik Koeln ( Site 0041)
Cologne, North Rhine-Westphalia, Germany
Universitaetsklinikum Muenster ( Site 0043)
Münster, North Rhine-Westphalia, Germany
IRCCS Ospedale San Raffaele ( Site 0051)
Milan, Italy
Fondazione PTV Policlinico Tor Vergata ( Site 0054)
Roma, Italy
Policlinico Umberto I ( Site 0056)
Roma, Italy
Policlinico Universitario Agostino Gemelli ( Site 0055)
Roma, Italy
ASST Spedali Civili di Brescia ( Site 0052)
Brescia, Lombardy, Italy
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 0121)
Hiroshima, Japan
National Hospital Organization Kumamoto Medical Center ( Site 0122)
Kumamoto, Japan
Jichi Medical University Hospital ( Site 0123)
Shimotsuke, Tochigi, Japan
Manchester Royal Infirmary ( Site 0097)
Manchester, United Kingdom
Freeman Hospital Newcastle upon Tyne Foundation NHS Trust ( Site 0092)
Newcastle upon Tyne, United Kingdom
Queen Elizabeth University Hospital [Glasgow, UK] ( Site 0096)
Glasgow, Glasgow City, United Kingdom
1Kings College Hospital ( Site 0091)
London, London, City of, United Kingdom
UCL Cancer Institute ( Site 0093)
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.